Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 476-482

  Zent, Clive S ^a   Wu, Wenting ^a   Bowen, Deborah A ^a   Hanson, Curtis A ^a   Pettinger, Adam M ^a   Shanafelt, Tait D ^a   Kay, Neil E ^a   Leis, Jose F ^b   Call, Timothy G ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Early treatment; GM CSF; High risk; Rituximab

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; BENDAMUSTINE; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PARACETAMOL; PENTOSTATIN; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER MORTALITY; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; MALE; PATIENT CARE; PATIENT MONITORING; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS REACTIVATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84873374136     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.717276     Document Type: Article

References (38)

1. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000: 343: 1910-1916.
2. Hamblin T, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94: 1848-1854.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94: 1840-1847.
4. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profle. Blood 2003;101: 4944-4951.
5. Tobin G, Tunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101: 4952-4957.
6. Zent CS, Kay NE. Managementofpatientswithchroniclymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma 2011;52: 1425-1434.
7. Pepper C, Majid A, Lin TT, et al. Def ning the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 2012: 156: 499-507.
8. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998;338: 1506-1514.
9. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists'Collaborative Group. J Natl Cancer Inst 1999: 91: 861-868.
10. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111: 5446-5456.
11. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23: 4079-4088.
12. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows signif cant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood 2007;109: 405-411.
13. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376: 1164-1174.
14. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010: 481-488.
15. Zent CS, Call TG, Shanafelt TD, et al. Early treatment ofhigh risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113: 2110-2118.
16. Zent CS, Secreto CR, Laplant BR, et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32: 1849-1856.
17. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms ofanti-CD20 monoclonal antibodies. Curr Opin Immunol 2008: 20: 444-449.
18. Faderl S, Tomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003: 101: 3413-3415.
19. Nabhan C, Patton D, Gordon L, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004: 45: 2269-2273.
20. Golay J, Manganini M, Rambaldi A, et al. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89: 1476-1483.
21. Siders WM, Shields J, Garron C, et al. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010: 51: 1293-1304.
22. Aufray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009: 27: 669-692.
23. Voso M, Pantel G, Rutella S, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by Effector cell-mediated mechanisms. Haematologica 2002;87: 918-925.
24. Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008;26: 2725-2731.
25. Ferrajoli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50: 514-516.
26. Morice WG, Kurtin PJ, Hodnefeld JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsyin252 patients. Mayo Clin Proc 2008;83: 776-785.
27. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87: 4990-4997.
28. Goldin LR, Lanasa MC, Slager SL, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol 2010;151: 152-158.
29. Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: Differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009: 113: 4188-4196.
30. Fleming TR. One sample multiple testing procedures for phase II clinical trials. Biometrics 1982: 38: 143-151.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958;53: 457-481.
32. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodef cient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26: 630-636.
33. Sohani AR, Ferry JA, Chang PS, et al. Epstein-Barr virus-positive dif use large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol 2010;28: e69-e72.
34. Tadmor T, Attias D, Polliack A. Myeloid-derived suppressor cells-their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 2011: 153: 557-567.
35. Seifert M, Schulz A, Ohl S, et al. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 2010: 116: 4223-4230.
36. Gustafson MP, Abraham RS, Lin Y, et al. Association of an increased frequency of CD14(+) HLA-DR(lo/neg) monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012;156: 674-676.
37. Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 2005;19: 1207-1210.
38. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007: 21: 956-964.